Manuka Ghosh
About
Manuka Ghosh is from Greater Boston. Manuka is currently Associate Director at Delix Therapeutics, located in Greater Boston. In Manuka's previous role as a Associate Director at PsychoGenics, Manuka worked in New Jersey until Jan 2022. Prior to joining PsychoGenics, Manuka was a Principal Scientist / Project Team Leader at Hsiri Therapeutics and held the position of Principal Scientist / Project Team Leader at Indiana. Prior to that, Manuka was a Research Fellow at CheminPharma LLC, based in Connecticut from Jan 2009 to Jan 2010. Manuka started working as Research Fellow II / Medicinal Chemistry Team Leader at Neurogen Corporation in Connecticut in Jan 2005. From Dec 2001 to Dec 2004, Manuka was Research Fellow I / Group Leader at Neurogen Corporation. Prior to that, Manuka was a Research Scientist II at Neurogen Corporation from Aug 2000 to Dec 2001. Manuka started working as Research Scientist I at Neurogen Corporation in Nov 1999.
Manuka Ghosh's email is available on Finalscout.com free of charge. This database has a wealth of information on over half a billion business professionals and two hundred million companies.
Manuka Ghosh's current jobs
Collaboration with CROs: SAI (India), Leadtech (China), Epics (Belgium), Frontier (DE), Cellectricon (Sweden), Workflow Informatics (NC). Projects / Indications: CNS disorder / Multiple indications Accomplishments: • Led a key program from initiation to develop novel selective serotonin receptor binders with neuroplasticity for complex brain disorders and discovered a potential Preclinical candidate (DLX-2270) with desired pharmacology and oral efficacy for Schizophrenia. • Directed the successful expansion of the DLX-chemical library with neuroplasticity-focused compounds by integrating machine learning in collaboration with a computational CRO. • Led a chemistry CRO team and collaborated with the scale-up vendor for the GLP route selection, synthesis, salt screening, and the supply of lead compounds on multiple-gram scales. • Oversaw in vitro CRO activity, coordinated compound inventory and logistics for timely delivery to global screening facilities, and managed electronic lab notebook and data maintenance on integrated cloud platforms (Bruker Arxspan ELN and CDD Vault).
Manuka Ghosh's past jobs
Collaboration with Karuna (MA), & CROs: TCGLS (India), WuXi (China), Collaborations Pharmaceuticals (NC). Projects / Indications: CNS disorder / Multiple indications Accomplishments: • Discovered pharmacologically novel, non-sedative anxiolytic leads and non-hallucinogenic psychedelic leads, pharmacologically distinct from LSD and Psilocybin, through data mining of PGI phenotype screening libraries and SmartCube technology. • Explored a novel pain and anticonvulsant project briefly to provide go/no-go decision. • Successfully managed an expansion of the PGI-CNS Chemical Library and led an external chemistry CRO.
Collaborations with Shionogi (Japan), AZ (MA), Merck (NJ) & CROs: PrakticaChem (China), KeraNetics (NC), Micromyx (MI), and TransPharm (MI) Medicinal Chemistry Project Leader (2011-Aug 2020): Accomplishments: • Discovered drug candidate HT-10, a novel daptomycin conjugate, for MDR Gram-negative bacterial infections. • Repurposed several conjugates of the Gram-positive-only antibiotics daptomycin as lead sideromycins (HT-12-HT-14) against virulent Gram-negative microbes. • Designed and developed a siderophore-biotin conjugate as a selective biosensor for detecting bacterial whole cells with potential in the diagnostic application. • Discovered Teicoplanin sideromycins for hospital-acquired fatal pneumonia.
• Designed and synthesized analogs (SAR) and compound library on RNA targets, riboswitch (Collaboration with Ribex, CT) • Participated in hit-to-lead and lead optimization to furnish preclinical anti-infective candidates.
• Discovered Melanin-Concentrating Hormone Receptor 1 (MCHR-1) antagonist drug candidate, NGD-0589, a potent anti-obesity agent (as a back-up of NGD-4715, Phase I), and participated in advancing the preclinical development candidate through IND-enabling studies. • Discovered Gamma-Aminobutyric Acid (GABA)-A alpha5 partial inverse agonist drug candidate NGD-2024 / CP-885316 (in collaboration with Pfizer) to treat cognitive symptoms in Alzheimer’s patients, as a backup to CP-457920 (Phase II). • Identified a lead Human Vanilloid Receptor 1 (VR1) antagonist for neuropathic pain (in collaboration with Merck). • Discovered lead Human Complement 5a (C5a) antagonists for acute inflammatory disorders. • Supervised PhD-level direct reports.
- Developed efficient syntheses of stereochemically diverse carbohydrate-based three-dimensional scaffolds, including the key scaffolds of moenomycin, a phosphoglycolipid antibiotic, for library generation and SAR studies. - Accomplished the total synthesis of ‘lipid I analog’ as a substrate for MurG enzyme. - Supervised 2 direct reports, PhD and MS level.